155 related articles for article (PubMed ID: 30209402)
21. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.
Garces S; Khoury JD; Kanagal-Shamanna R; Salem A; Wang SA; Ok CY; Hu S; Patel KP; Routbort MJ; Luthra R; Tang G; Schlette EJ; Bueso-Ramos CE; Medeiros LJ; Loghavi S
Hum Pathol; 2018 Dec; 82():215-231. PubMed ID: 30086334
[TBL] [Abstract][Full Text] [Related]
22. Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.
Tausch E; Mertens D; Stilgenbauer S
Oncol Res Treat; 2016; 39(1-2):34-40. PubMed ID: 26890126
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Saddler C; Ouillette P; Kujawski L; Shangary S; Talpaz M; Kaminski M; Erba H; Shedden K; Wang S; Malek SN
Blood; 2008 Feb; 111(3):1584-93. PubMed ID: 17971485
[TBL] [Abstract][Full Text] [Related]
24. A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.
Amin NA; Seymour E; Saiya-Cork K; Parkin B; Shedden K; Malek SN
Clin Cancer Res; 2016 Sep; 22(17):4525-35. PubMed ID: 27060156
[TBL] [Abstract][Full Text] [Related]
25. Conventional cytogenetics in chronic lymphocytic leukemia (CLL).
Krings Rocha C; Wendtner CM; Hallek M; Kreuzer KA
Leuk Res; 2011 Mar; 35(3):e25. PubMed ID: 21074268
[No Abstract] [Full Text] [Related]
26. Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility.
Goldin LR; McMaster ML; Rotunno M; Herman SE; Jones K; Zhu B; Boland J; Burdett L; Hicks B; Ravichandran S; Luke BT; Yeager M; Fontaine L; Goldstein AM; Chanock SJ; Tucker MA; Wiestner A; Marti G; Caporaso NE
Blood; 2016 Nov; 128(18):2261-2263. PubMed ID: 27629550
[No Abstract] [Full Text] [Related]
27. Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia.
Alsagaby SA; Alhumaydhi FA
Saudi Med J; 2019 Apr; 40(4):317-327. PubMed ID: 30957124
[TBL] [Abstract][Full Text] [Related]
28. Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.
Oliveira-Santos W; Rabello DA; Lucena-Araujo AR; de Oliveira FM; Rego EM; Pittella Silva F; Saldanha-Araujo F
Tumour Biol; 2016 Jul; 37(7):9473-81. PubMed ID: 26790435
[TBL] [Abstract][Full Text] [Related]
29. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.
Knight SJ; Yau C; Clifford R; Timbs AT; Sadighi Akha E; Dréau HM; Burns A; Ciria C; Oscier DG; Pettitt AR; Dutton S; Holmes CC; Taylor J; Cazier JB; Schuh A
Leukemia; 2012 Jul; 26(7):1564-75. PubMed ID: 22258401
[TBL] [Abstract][Full Text] [Related]
30. Concomitant telomere shortening, acquisition of multiple chromosomal aberrations and in vitro resistance to apoptosis in a single case of progressive CLL.
Brugat T; Nguyen-Khac F; Merle-Béral H; Delic J
Leuk Res; 2011 May; 35(5):e37-40. PubMed ID: 21176960
[No Abstract] [Full Text] [Related]
31. Chronic lymphocytic leukemia.
Wierda WG; Kipps TJ
Curr Opin Hematol; 1999 Jul; 6(4):253-61. PubMed ID: 10400375
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
Baghaei Vaji F; Boroumand Nasr A; Rezvani A; Ayatollahi H; Goudarzi S; Lavasani S; Bagheri R
Leuk Res; 2021 Dec; 111():106729. PubMed ID: 34735935
[TBL] [Abstract][Full Text] [Related]
33. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
34. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.
Buhl AM; Jurlander J; Geisler CH; Pedersen LB; Andersen MK; Josefsson P; Petersen JH; Leffers H
Eur J Haematol; 2006 Jun; 76(6):455-64. PubMed ID: 16529606
[TBL] [Abstract][Full Text] [Related]
35. [The genetic landscape of chronic lymphocytic leukemia].
Marosvári D; Alpár D; Király AP; Rajnai H; Reiniger L; Bödör C
Magy Onkol; 2016 Jun; 60(2):118-25. PubMed ID: 27275638
[TBL] [Abstract][Full Text] [Related]
36. Chronic lymphocytic leukemia: biology and current treatment.
Zent CS; Kay NE
Curr Oncol Rep; 2007 Sep; 9(5):345-52. PubMed ID: 17706162
[TBL] [Abstract][Full Text] [Related]
37. IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC.
Benatti S; Atene CG; Fiorcari S; Mesini N; Martinelli S; Zucchini P; Bacchelli F; Maccaferri M; Debbia G; Potenza L; Rossi D; Vallisa D; Trentin L; Gaidano G; Luppi M; Marasca R; Maffei R
Hematol Oncol; 2021 Dec; 39(5):707-711. PubMed ID: 34431535
[No Abstract] [Full Text] [Related]
38. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
[TBL] [Abstract][Full Text] [Related]
39. MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?
Van Roosbroeck K; Calin GA
Semin Oncol; 2016 Apr; 43(2):209-14. PubMed ID: 27040698
[TBL] [Abstract][Full Text] [Related]
40. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
